Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer's Risk to Include Saliva Samples
Cytox, a precision medicine testing company commercializing polygenic risk scoring (PRS) and other approaches for assessing genetic risk for developing Alzheimer’s disease, has collaborated with integrated genomics and genetics leader AKESOgen to verify the performance of the Cytox geno BAR™ test with saliva samples.
The geno BAR research test is intended to help pharma, biotech and sponsors of large cohort studies reduce the time and high cost associated with identifying and stratifying subjects for clinical trials and large population research, which can take more than six months and run to tens of thousands of dollars per participant. The work performed by Cytox and AKESOgen resulted in over 99% concordance between the SNPs used in the PRS identified from blood and saliva samples collected from the same subjects and run on the Cytox varia TECT™ microarray on the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform from Thermo Fisher Scientific. The saliva samples were collected using the DNA Genotek DNA saliva kit. The results of this verification study will provide an additional means to collect DNA from prospective clinical trial and cohort subjects and opens the possibility of screening even larger population groups for disease risk.
“The extension of our test to include saliva samples in addition to blood samples and biobanked DNA represents a significant step forward,” commented Dr Richard Pither, CEO of Cytox, “Our customers in pharma and biotech now have the ability to collect larger numbers of samples in a highly efficient and non-invasive way, opening the doors to the cost-effective screening of tens to hundreds of thousands of prospective clinical study participants, or still larger population networks associated with regional healthcare centres or national dementia programmes.”
Dr Mark Bouzyk, Chief Scientific Officer at AKESOgen, added, “The collaboration between AKESOgen and Cytox aims to ensure the highest accuracy possible across all the biological samples types generally used for genetic analysis. We believe these results and our partnership with Cytox will eventually result in more effective screening and diagnosis for those patients impacted by Alzheimer’s disease."
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
TX-PLANVIEW18.2.2019 16:07:07 | Pressemeddelelse
Planview Empowers Organizations to Realize Agile-at-Scale with Lean and Agile Delivery Solution
LUXEMBOURG-SPACE-AGENCY18.2.2019 15:09:03 | Pressemeddelelse
The University of Luxembourg Launches a Unique Interdisciplinary Space Master in Line with the Government’s SpaceResources.lu Initiative
NJ-WIPRO18.2.2019 14:57:02 | Pressemeddelelse
Wipro Launches QuMiC to Accelerate Migration to Oracle Cloud
FL-STERLING-LEXICON18.2.2019 14:49:12 | Pressemeddelelse
Top Mobility Firms Combine to Form Sterling Lexicon
MILREM-ROBOTICS18.2.2019 14:02:07 | Pressemeddelelse
Milrem Robotics’ THeMIS UGV Strengthens Its Position as The Industry Standard
MASIMO18.2.2019 14:02:07 | Pressemeddelelse
Saudi Arabia Ministry of Health and Masimo Announce Automation of National Neonatal CCHD Screening Process Using Masimo Technology
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum